Evidence map›Paper›PMID 38299570›Full record

Trial reportThe Journal of urology2024

Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression.

Misty D Bechtel, Carrie Michel, Pugazhendhi Srinivasan, Prabhakar Chalise, William P Parker, Moben Mirza, Brantley Thrasher, Heather D Gibbs, John DiGiovanni, Jill Hamilton-Reeves

Open access · greenAbstract readRandomized Controlled TrialClinical Trial, Phase II
In one paragraph

Trial report in The Journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Misty D BechtelDepartment of Urology, University of Kansas Medical Center, Kansas City, Kansas.
Carrie MichelDepartment of Urology, University of Kansas Medical Center, Kansas City, Kansas.
Pugazhendhi SrinivasanDepartment of Urology, University of Kansas Medical Center, Kansas City, Kansas.
Prabhakar ChaliseDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
William P ParkerDepartment of Urology, University of Kansas Medical Center, Kansas City, Kansas.
Moben MirzaDepartment of Urology, University of Kansas Medical Center, Kansas City, Kansas.
Brantley ThrasherDepartment of Urology, University of Kansas Medical Center, Kansas City, Kansas.
Heather D GibbsDepartment of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, Kansas.
John DiGiovanniDivision of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas.
Jill Hamilton-ReevesDepartment of Urology, University of Kansas Medical Center, Kansas City, Kansas.ORCID 0000-0002-0973-1542
University of Kansas Medical Center · USLivestrong Foundation · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
NCI NIH HHS P30 CA168524
6 · The paper itself

Abstract

purposeExcess body and visceral fat increase the risk of death from prostate cancer (PCa). This phase II study aimed to test whether weight reduction by > 5% total body weight counteracts obesity-driven PCa biomarkers. MATERIALS AND

methodsForty men scheduled for prostatectomy were randomized into intervention (n = 20) or control (n = 20) arms. Intervention participants followed a weight management program for 4 to 16 weeks before and 6 months after surgery. Control participants received standardized educational materials. All participants attended visits at baseline, 1 week before surgery, and 6 months after surgery. Circulating immune cells, cytokines, and chemokines were evaluated. Weight loss, body composition/distribution, quality of life, and nutrition literacy were assessed. Prostate tissue samples obtained from biopsy and surgery were analyzed.

resultsFrom baseline to surgery (mean = 5 weeks), the intervention group achieved 5.5% of weight loss (95% CI, 4%-7%). Compared to the control, the intervention also reduced insulin, total cholesterol, LDL cholesterol, leptin, leptin:adiponectin ratio, and visceral adipose tissue. The intervention group had reduced c-peptide, plasminogen-activator-inhibitor-1, and T cell count from baseline to surgery. Myeloid-derived suppressor cells were not statistically different by group. Intervention group anthropometrics improved, including visceral and overall fat loss. No prostate tissue markers changed significantly. Quality of life measures of general and emotional health improved in the intervention group. The intervention group maintained or kept losing to a net loss of 11% initial body weight (95% CI, 8%-14%) at the study end.

conclusionsOur study demonstrated improvements in body composition, PCa biomarkers, and quality of life with a weight management intervention.

Indexed as

LeptinProstatic NeoplasmsAdipose TissueBiomarkersBody WeightHumansMaleObesityProstateQuality of LifeWeight LossBiomarkersLeptinobesityprostate cancerquality-of-lifevisceral fatweight loss

Identifiers

PMID38299570
PMCPMC11887940
OpenAlexW4391436398

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.